GE touts flutemetamol study results

March 8, 2012

GE Healthcare is touting the results of two studies that suggest the company's investigational imaging agent F-18 flutemetamol could combine with other diagnostic tools to evaluate neurodegenerative conditions such as Alzheimer's disease.